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We performed allogeneic hematopoietic stem cell transplantation in 6 patients with mutations in the
dedicator-of-cytokinesis-8 (DOCK8) gene using a myeloablative conditioning regimen consisting of busulfan
3.2 mg/kg/day i.v. for 4 days and ﬂudarabine 40 mg/m2/day for 4 days. Three patients received allografts from
matched related donors and 3 patients from matched unrelated donors. Two patients received peripheral
blood stem cells and 4 patients bone marrow hematopoietic stem cells. Tacrolimus and short-course
methotrexate on days 1, 3, 6, and 11 were used for graft-versus-host-disease (GVHD) prophylaxis. All 6 pa-
tients are alive at a median follow-up of 22.5 months (range, 14 to 35). All patients achieved rapid and high
levels of donor engraftment and complete reversal of the clinical and immunologic phenotype. Adverse
events consisted of acute skin GVHD in 2 patients and post-transplant pulmonary inﬁltrates in a patient with
extensive bronchiectasis pretransplant. Thus, a uniform myeloablative conditioning regimen followed by
allogeneic hematopoietic stem cell transplantation in DOCK8 deﬁciency results in reconstitution of immu-
nologic function and reversal of the clinical phenotype with a low incidence of regimen-related toxicity.
Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.INTRODUCTION
The genetic defect in most autosomal recessive hyper-IgE
syndrome cases was shown to be due to homozygous or
compound heterozygous mutations in the dedicator-of-
cytokinesis-8 (DOCK8) gene [1,2]. Consanguinity is highly
correlated with homozygous mutations in DOCK8, whereas
most instances of DOCK8 deﬁciency arising in the absence of
a family history of the disease are compound heterozygotesdgments on page 1044
equests: Dr. Dennis D. Hickstein, 9000
2, Bethesda, MD 20892.
nih.gov (D.D. Hickstein).
15.01.022
c. on behalf of American Society for Blood andwith a different mutation in DOCK8 on each allele. DOCK8 is
an atypical guanine nucleotide exchange factor that medi-
ates guanosine triphosphateeguanosine diphosphate ex-
change on Cdc42, a member of the Rho family of GTPases [3].
DOCK8 deﬁciency results in a constellation of clinical signs
that encompass allergic/atopic manifestations, infection, and
malignancy, including severe cutaneous and sinopulmonary
infections with bacterial organisms, severe mucocutaneous
viral infections with herpes simplex (HSV), cutaneous and
disseminated infections with varicella-zoster virus, severe
and often debilitating Molluscum contagiosum and human
papilloma virus infections, systemic infections with other
herpes viruses such as Epstein-Barr virus (EBV), fungalMarrow Transplantation.
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histoplasmosis, Pneumocystis jirovecii pneumonia, and severe
parasitic infections with Cryptosporidium parvum [1,2]. Most
patients with DOCK8 deﬁciency display marked elevation in
serum IgE levels and eosinophils with severe eczema and
multiple food and drug allergies. Finally, these patients have
the propensity to develop human papilloma virusedriven
squamous cell carcinomas and lymphomas, including those
driven by EBV [1,2]. Patients with DOCK8 deﬁciency typically
present during childhood, and most die by their early
twenties from infection, squamous cell carcinoma, or
lymphoma.
Many primary immunodeﬁciency diseases (PIDs) such as
DOCK8 deﬁciency are caused by intrinsic genetic defects of
hematopoietic lineage-derived cells for which allogeneic
hematopoietic stem cell transplantation (HSCT) represents
an effective therapeutic approach. The life-threatening in-
fections and malignant transformation arising from poor
immune surveillance in DOCK8 deﬁciency and the high
likelihood of death at a young age support a deﬁnitive
therapeutic approach with allogeneic HSCT.
Allogeneic HSCT has been shown to reverse the phenotype
in DOCK8 deﬁciency by reconstituting the normal host de-
fense [4-11]. However, reports of HSCT in DOCK8 deﬁciency
typically consist of case studies with heterogeneous condi-
tioning regimens, including several in which DOCK8 deﬁ-
ciency was identiﬁed only retrospectively. Here we describe
successful allogeneic HSCT for prospectively diagnosed pa-
tients with DOCK8 deﬁciency using matched related and
unrelated donors and a uniform, reduced-toxicity, high-dose
regimen of busulfan and ﬂudarabine without serotherapy.METHODS
Study Design and Procedures
We conducted a phase I pilot study to determine the efﬁcacy and safety
of myeloablative allogeneic HSCT for patients with DOCK8 deﬁciency. The
primary objective of the study was to determine whether allogeneic HSCT
reconstitutes T lymphocyte and B lymphocyte cells and myeloid cells with
normal donor cells at 1 year post-transplant and reverses the clinical
phenotype of severe recurrent infections in patients with DOCK8 deﬁciency.
The secondary objective of the study was to determine the safety of this
allogeneic transplant regimen in DOCK8 deﬁciency by assessing transplant-
related toxicity, the incidence of acute and chronic graft-versus-host dis-
ease (GVHD), immune reconstitution, overall survival, and disease-free
survival.
The study was approved by the Institutional Review Board of the
National Cancer Institute and was independently monitored for safety and
data accuracy. Written informed consent and assent was obtained for all
patients and donors (ClinicalTrials.gov number, NCT01176006).
Inclusion criteria were as follows: (1) patient age of 8 to 40 years, (2)
DOCK8 deﬁciency with clinical history of 1 or more episodes of life-
threatening or severely disﬁguring infection with opportunistic organisms,
(3) homozygous or compound heterozygous mutations in the DOCK8 gene
performed by a Clinical Laboratory Improvement Amendments (CLIA)-
certiﬁed laboratory, (4) 10/10 or 9/10 HLA-matched related or unrelated
donor or a haploidentical related donor, (5) left ventricular ejection fraction
> 40%, (6) pulmonary function tests with forced expiratory volume in 1
second > 20% of expected value, (7) adult patients < 2.0 mg/dL or creatinine
clearance > 30 mL/min/1.73 m2 and pediatric patients (<18 years old)
creatinine < 1.5 mg/dL or a creatinine clearance > 30 mL/min/1.73 m2, (8)
serum total bilirubin < 2.5 mg/dL and serum alanine and aspartate ami-
notransferases  5 times upper limit of normal, (9) central venous access
potential, and (10) written informed consent/assent obtained from patient/
parent or legal guardian. Exclusion criteria consisted of (1) age < 8 years or
>40 years, (2) HIV infection, (3) chronic active hepatitis B infection, (4)
active central nervous system involvement by malignancy, (5) pregnant or
lactating, (6) presence of active malignancy in another organ system other
than the hematopoietic system (except when driven by viruses, in which
case the immune reconstitution after transplant may control the malig-
nancy), and (7) no available 10/10 or 9/10 HLA-matched related or unrelated
donor or haploidentical donor.Transplant Regimen
The pretransplant conditioning regimen consisted of ﬂudarabine 40mg/
m2/day i.v. on days 6, 5, 4, and 3 and busulfan 3.2 mg/kg on the same
4 days. Fludarabine was dosed based on actual body weight and adjusted for
renal dysfunction. One patient (Patient 6) received dose-adjusted busulfan
with the actual dose based on a test dose of .8 mg/kg of busulfan given
before the start of the preparative regimen [12-14]. The purpose of the
busulfan test dose was to obtain pharmacokinetic blood samples of busulfan
for calculation of an area under the curve (AUC).
For the single patient who received the test dose of busulfan, the
busulfan-conditioning dose was calculated to obtain a target AUC of 3600 to
4800 mM/min based on the discretion of the principle investigator to mini-
mize toxicity in patients with an exceptionally high clearance. The busulfan
test dose was given as a 2-hour infusion, and 4 busulfan blood samples
were drawn after the administration of the test dose. The ﬁrst specimen was
drawn immediately after termination of the 2-hour i.v. infusion of .8 mg/kg
busulfan. Additional specimens were drawn at 1, 2, and 4 hours after termi-
nation of infusion. All samples were sent to the Mayo Medical Laboratories.
Busulfan dose ¼ target AUC of 3600 to 4800 mM/min  test dose (mg)
divided by the
Test dose AUC (mM/min)
The calculated busulfan dose was administered by i.v. infusion over 3
hours once daily for 4 doses (days 6, 5, 4, and 3) by a controlled-rate
infusion pump through a central venous catheter. Busulfan dosing (test dose
and full conditioning regimen [days 6, 5, 4, and 3]) was based on the
recipient’s ideal body weight or actual body weight, whichever was lower.
Donors
Matched related and unrelated donor peripheral blood stem cells
(PBSCs) or bone marrow cells were infused fresh on day 0. Matched related
and unrelated donors providing PBSCs received 5 days of granulocyte
colony-stimulating factor (10 mg/kg/day), followed by apheresis on day 5
with the goal of collecting at least 5  106 CD34þ cells/kg of the recipient’s
body weight. The target dose of bone marrow was 2  108 total nucleated
cells/kg recipient body weight. Mutation on 1 allele of DOCK8 did not
represent exclusion criteria.
Post-Transplant GVHD Prophylaxis
GVHD prophylaxis consisted of tacrolimus (target level of 5 to 10 ng/mL)
starting on day 3 and short-course methotrexate 5 mg/m2 i.v. on
days þ1, þ3, þ6, and þ11. Immunosuppression was tapered at 6 months
post-transplant if there was no evidence of GVHD.
CD4 and CD8 T Cells
CD4þ and CD8þ T lymphocytes, B cells, and natural killer (NK) cells were
quantiﬁed by ﬂow cytometry pretransplant and at designated intervals
post-transplant.
Lymphocyte Subset Immunophenotyping
Lymphocyte subsets were analyzed before and after transplant by ﬂow
cytometry to identify CD4þ and CD8þ T cells, CD3þ/CD8þ/CD45RAþ/CCR7þ
(naïve CD8 T cells), CD3þ/CD8þ/CD45RA (memory CD8 T cells), CD3þ/CD8þ/
CD45RAþ/CCR7 (T cell effector memory CD45RAþ CD8 T cells), CD3þ/CD8þ/
CD45RA/CD127þ (CD8 memory T cells expressing IL-7Ra), CD3þ/CD8þ/
CD38þ/CD57þ (exhausted CD8 T cells), and CD3þ/CD8þ/CD45RAþ/CCR7þ/
CD95þ (naive CD8 T cells abnormally expressing CD95). B cell analysis
consisted of CD19þ/CD27 (naive B cells), CD19þ/CD27þ/IgDþ (unswitched
memory B cells; marginal zone-like B cells), CD19þ/CD27þ/IgD (switched
memory B cells), and CD19þ/CD24hi/CD38hi (transitional B cells).
Analysis of Chimerism
Engraftment of donor cells was assessed using polymorphisms in
regions known to contain short tandem repeats. Peripheral blood CD4þ and
CD8þ T lymphocytes and CD19þ and CD3/CD56þ lymphocytes were
selected by cell sorting using ﬂow cytometry at the designated time points,
and chimerism was assessed on these subpopulations. In addition, CD14þ/
CD15þ myeloid cells and CD3þ T lymphocytes were selected using immu-
nobeads, and chimerism was assessed on the selected cells. The lower limit
of sensitivity for this method is 1% to 3% of donor-type polymorphic markers
in the mixture; these sensitivities are based on studies using mixtures of
knownproportions of allogeneic DNA samples. Chimerismwas also assessed
on bone marrow aspirate at designated time points.
Supportive Care
We followed standard guidelines for supportive care established at the
National Institutes of Health Clinical Research Center for patients under-
going allogeneic HSCT.
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A paired t-test was used to compare the leukocyte subsets pretransplant
and at 1 year post-transplant.
RESULTS
Characteristics of Patients
The clinical characteristics of the 6 patients with DOCK8
deﬁciency receiving allogeneic HSCT are summarized
(Table 1). The median age of the recipients was 20.5 years
(range, 10 to 27). DNA viral infections and recurrent bacterial
infections were present in all patients. All 6 patients had a
history of eczema, although the eczema in 2 patients
improved early in life and was not present at the time of
conditioning. Three patients also had signiﬁcant food al-
lergies. Pulmonary complications were also ubiquitous.
Three patients had markedly elevated IgE levels, consistent
with DOCK8 deﬁciency as an autosomal recessive hyper-IgE
syndrome. Two patients were homozygous for DOCK8 mu-
tations due to consanguinity, and the other 4 patients were
compound heterozygotes for DOCK8 mutations.
These patients shared many clinical features; however,
each patient had a unique constellation of clinical signs that
led to transplant. Patient 1 had a refractory HSV gingivitis
and periodontitis (Figure 1), severe refractory eczema
(Figure 2A), and recurrent otitis and sinopulmonary in-
fections with bronchiectasis and hearing loss. Patient 2 had
severe, refractory eczema with recurrent bacterial skin in-
fections and viral infections (Figure 2C), recurrent purulent
otitis, and pneumonia. Patient 3 had severe primary
varicella-zoster virus as a child and Neisseria Neisseria men-
ingitis multifocal septic arthritis as an adolescent. Patient 4
had partial vision loss due to recurrent HSV keratitis,
extensive warts (Figure 2B), squamous cell carcinoma in situ,
and recurrent sinopulmonary infections. Patient 5 had severe
bronchiectasis from recurrent pulmonary infections result-
ing in severe obstructive and restrictive ventilatory defects.
She was oxygen dependent at the time of transplant and had
been evaluated for a lung transplant. Patient 6 had
chemotherapy-refractory, EBV-virus driven lymphoma.
Before transplantation, all infections were treated
aggressively. To minimize infections during neutropenia
related to abnormal skin barriers from eczema, Patients 1
and 2 received wet wrap therapy the week before condi-
tioning. Wet wrap therapy was performed 3 times daily for
several days, using triamcinolone .1% ointment for lesions on
the body and desonide .05% ointment for lesions on the face,
with substantial restoration of the skin barrier.
Transplantation Outcomes
The objectives of this study were to determine whether
allogeneic HSCT reconstitutes T lymphocyte and B lympho-
cyte cells and myeloid cells with normal donor cells at 1 year
post-transplant and reverses the clinical phenotype of severe
recurrent infections in patients with DOCK8 deﬁciency. The
secondary objective of the study was to determine the safety
of this allogeneic transplant regimen in DOCK8 deﬁciency by
assessing transplant-related toxicity, incidence of acute and
chronic GVHD, immune reconstitution, overall survival, and
disease-free survival. Wewere also interested inwhether the
donor source might inﬂuence engraftment or outcome.
Three patients received matched related donor trans-
plants and 3 received matched unrelated donor transplants
(Table 2). Bone marrow was the preferred donor source and
was obtained in all 3 matched related donors and in 1 of 3
matched unrelated donors. Table 2 shows the composition ofdonor grafts. Themedian CD34þ cells infused were 5.2 106/
kg, and the median CD3þ cells infused were 1.98  107/kg.
Two of 3 matched related donors (Patients 1 and 2) were
heterozygous for the mutant DOCK8 allele.
All patients engrafted, and the neutrophil engraftment
(deﬁned as a neutrophil count > .5  109 cells/L for 3
consecutive days) was rapid in all patients, with a mean of
10.5 days (range, 10 to 20). The median duration of neu-
tropenia was only 5.5 days (range, 4 to 15). The median time
to platelet engraftment (deﬁned as a platelet count > 20 
109 cells/L for 7 consecutive days without requiring platelet
transfusion) was 18 days (range, 15 to 31). There were no
instances of graft rejection. All patients were alive at a me-
dian follow-up of 22.5 months (range, 14 to 35).
All patients had a marked improvement or complete
resolution of gingivitis (Figure 1), skin manifestations
(Figure 2), and infection susceptibility by 100 days post-
transplant. However, all patients had a transient worsening
of their pretransplant bacterial infections (sinopulmonary)
or warts between 1 and 3 months post-transplant. Eczema
signiﬁcantly improved or resolved in the patients presenting
with eczema at baseline.
The patient with the chemotherapy-refractory, EBV-
driven, diffuse large B cell lymphoma (Patient 6) had a
complete response by positron emission tomography 100
days after unrelated donor PBSC transplant (Figure 3).
However, because of the burden of disease pretransplant and
because she had failed many cycles of chemotherapy before
transplant, she received an infusion of donor-derived, EBV-
speciﬁc cytotoxic T lymphocytes 4 months post-transplant at
Baylor University [15]. At 1 year post-HSCT she had no
detectable EBV viremia and showed complete resolution by
positron emission/computed tomography.
All 6 patients are outpatients and return for their follow-
up visits at 3- to 6-month intervals. Only the most recently
transplanted patient remains on immunosuppression for
skin GVHD, and he is tapering off tacrolimus.
Reconstitution of normal donor hematopoiesis was
achieved in all 6 patients. All patients achieved 99% to 100%
donor myeloid cells as well as 99% to 100% CD4þ and CD8þ T
lymphocytes and CD19þ B cells at 30 days and 1 year post
HSCT (Table 3). In addition, all 6 patients had greater than 94%
donor bone marrow chimerism at 1 year post-transplant
(Table 3).
Correction of the cellular compartments that were deﬁ-
cient pretransplant represented a primary objective of this
study. Statistically signiﬁcant increases in CD4 T cells and
CD19þ B cells were observed; however, improvements in
CD8 T cells and NK cells did not achieve statistical signiﬁ-
cance at 1 year, most likely due to continued immunosup-
pression in 2 patients (Figure 4). Two markers of the DOCK8
deﬁciency, elevated IgE levels and eosinophilia, improved
post-transplant. The mean IgE level pretransplant was 4137
IU/mL (normal, 0 to 90) and 1 year post-transplant was 542
IU/mL (normal, 0 to 90). Similarly, eosinophil levels dropped
from 316/mL (normal, 40 to 360) pretransplant to 181/mL
(normal, 40 to 360) post-transplant. However, there was a
very large standard deviation in both measurements due to
the heterogeneity of the patients. Also, atopic manifestations
persisted post-transplant in most patients, consistent with
the IgE levels that remained above normal.
Detailed lymphocyte subset analyses before and 1 year
after transplant for Patients 4 and 5 are shown (Supplemental
Table 1). CD4þ T cells signiﬁcantly increased post-transplant,
whereas CD8þ T cells decreased in both. Naive CD8þ T cells
Table 1
Baseline Characteristics of Patients with DOCK8 Deﬁciency Receiving HSCT
Donor Age at
HSCT
(yr)/Sex
Type of Infections Eczema Pulmonary
Complications
Other IgE DOCK8 Mutation
Viral Other
1 MRD 18/F HSV,
mucocutaneous
refractory
HPV, skin
EBV viremia
Recurrent bacterial
sinusitis/
pneumonias/otitis
Severe Bronchiectasis
Restrictive
ventilatory defect
Hearing loss 8031 Homozygous
Del exons 28-35
2 MRD 10/F HPV, skin
EBV viremia
Recurrent bacterial sinusitis/
pneumonias/otitis
Severe None 5243 Homozygous
c.2044 G>T (E682X)
3 MRD 23/M HPV, skin
M. contagiosum
VZV, disseminated
Disseminated N. meningitides
Recurrent bacterial sinusitis/
pneumonias
Moderate Restrictive ventilatory defect 11,279 Compound heterozygous
c.1153 G>T (E385X)
Deletion of DOCK8
4 URD 27/M HPV, skin,
M. contagiosum
HSV, keratitis recurrent
EBV viremia
Recurrent bacterial sinusitis/
pneumonias
Moderate Bronchiectasis Partial vision loss 118 Compound heterozygous c.1266delC
(p.Try423ThrfsX18)
Del exons 2-47
5 URD 25/F HPV, skin and genital
M. contagiosum
EBV viremia
Recurrent bacterial sinusitis/
pneumonias
Resolved
pre-HSCT
Bronchiectasis, severe
Obstructive/restrict ventilatory defects
O2 dependent
8.3 Compound heterozygous
c.1266delC (p.Try423ThrfsX18)
Del exons 2-47
6 URD 16/F Skin HPV
EBV malignancy
Recurrent bacterial sinusitis/
pneumonias
Mild Obstructive/restrict ventilatory defects EBV
Lymphoma
143 Compound heterozygous
c.1805G>A (p.W602X)
c.4540delG (p.E1514KfsX8)
MRD indicates matched related donor; HPV, human papilloma virus; M. contagiosum, Molluscum contagiosum; VZV, varicella-zoster virus; N. meningitides, Neisseria meningitides; URD, unrelated donor.
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Figure 1. Correction of the oral manifestations of DOCK8 deﬁciency. (A) Refractory HSV gingivitis and (B) periodontitis in Patient 1. (C and D) Post-transplant
day þ100 in the same patient.
J. Cuellar-Rodriguez et al. / Biol Blood Marrow Transplant 21 (2015) 1037e1045 1041increased post-transplant. Although effector/memory CD8þ T
cells decreased in only 1 of the 2 patients, terminally differ-
entiated, “exhausted” CD8þ effectormemory CD45RAþTcells
decreased in both patients. The latter was consistent with the
interpretation that these patients had active inﬂammation
pretransplant, leading to a relative depletion of the naive
CD8þ T cells pretransplant, and after transplant the immu-
nologic system was achieving equilibrium. AberrantlyFigure 2. Cutaneous lesions in DOCK8 patients. (A) Severe persistent eczematous de
conﬂuent verrucae on the antecubital fossa and knees of Patient 4 before and after Hdifferentiated naive T cells expressing CD95, which were
previously reported in DOCK8-deﬁcient patients, also
normalized after transplant [16]. By contrast, the increased
naive B cells and decreased memory B cells, consistent with
that previously reported in DOCK8-deﬁcient patients [17],
were not corrected at 1 year after transplant, although the
increased transitional B cells in 1 patient did improve. These
results may reﬂect the fact that recovery of donor B cellrmatitis on dorsal feet of Patient 1 before and after HSCT. (B) Extensive bulky,
SCT. (C) Chronic wounds on hands and legs of Patient 2 before and after HSCT.
Table 2
Characteristics of Hematopoietic Stem Cell Grafts and Outcome of HSCT
Donor Cell Source HLA Match Composition of Donor Graft Infections Post-HSCT GVHD Outcome/Follow-Up
(mo)
CD34þ 106/kg CD3þ 107/kg
1 MRD BM 10/10 5.4 1.35 URI, otitis, pneumonia Acute grade II skin Alive/23
2 MRD BM 10/10 7 1.86 URI, otitis No Alive/16
3 MRD BM 10/10 3.5 2.1 HHV-6 viremia, URI Acute grade III skin Alive/14
4 URD PBSC 10/10 5 17.6 BSI, C. difﬁcile No Alive/35
5 URD BM 10/10 5 5 Pneumonia Possible BOS Alive/25
6 URD PBSC 10/10 7.5 1.45 Pneumonia, otitis No Alive/22
BM indicates bone marrow; URI, upper respiratory infection; HHV-6, human herpes virus 6; BSI, bloodstream infection; C. difﬁcile, Clostridium difﬁcile; BOS,
bronchiolitis obliterans syndrome.
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has been observed in hematopoietic transplantation for
other PIDs.
Adverse Events
We anticipated major complications with HSCT in this
group of patients. Mucositis and toxic erythema of chemo-
therapy were the major side effects of the transplant-
conditioning regimen. As mentioned previously, all patients
had transientworsening of sinopulmonary inﬂammation after
HSCT, but all responded to antimicrobial therapy, suctioning,
sinus drainage, or the short-term use of bronchodilators. The
patient with the EBV lymphoma (Patient 6) had an extensive
lungmass and post-transplant developed a complete left lung
collapse from a mucous plug. Bronchoscopy resulted in com-
plete re-expansion of the collapsed lung. Acute GVHD of the
skin developed in 2 patients: 1 responded to topical steroids
and 1 required systemic steroids. The patient with the exten-
sive bronchiectasis and severe lung dysfunction pre transplant
(Patient 5) had improvement of her pulmonary defects post-
transplant and was able to discontinue oxygen. However,
shortly after her immunosuppression was stopped, her lung
disease worsened, requiring reinitiating of immunosuppres-
sion.However, she isnow25monthspost-transplant andoff all
immunosuppression.DISCUSSION
Here we report that related and unrelated donor alloge-
neic HSCT with the combination of busulfan and ﬂudarabine
results in reliable engraftment and reversal of the clinical
phenotype in patients with DOCK8 deﬁciency with a lowFigure 3. Positron emissions tomography scan of EBV-positive lymphoma in Patient 6regimen-related toxicity. DOCK8 deﬁciency, a form of auto-
somal recessive hyper-IgE syndrome, remains a lethal dis-
ease in which patients succumb to complications of
infections or malignant transformation. HSCT represents the
only curative therapy. There is controversy as to the ideal
timing of HSCT in DOCK8 deﬁciency, but the development of
life-threatening infections, end-organ damage, and malig-
nancy are strong indicators that HSCT should be considered
earlier in the clinical course, before these complications
develop.
Over the preceding decades, HSCT has been shown to
reverse the phenotype in a variety of PIDs. However, the
optimal conditioning regimen for HSCT in PID has yet to be
deﬁned. In the most extensive use of reduced-intensity
conditioning in patients with PID receiving unrelated donor
HSCT, Veys et al. [18] demonstrated a 94% survival rate in 33
patients treated with a reduced-intensity regimen consisting
of melphalan 140 mg/m2, ﬂudarabine 150 mg/m2, and
alemtuzumab (Campath 1H 1 mg/kg). They observed rapid
engraftment in 32 of 33 patients with neutrophil recovery at
13 days and platelet recovery at 16 days. Of note, at 1 year
post-transplant only 55% of patients had 100% donor
chimerism. Possibly as a result of the low level of complete
donor chimerism, only 9% of patients in the reduced-
intensity conditioning group had acute GVHD more than
grade II. However, there was also a very high rate of viral
reactivation associated with the use of alemtuzumab.
In a study of 70 childrenwith PIDwho received 42 g/m2 or
36 g/m2 treosulfan with cyclophosphamide 200 mg/kg (n ¼
30) or ﬂudarabine 150 mg/m 2 (n ¼ 40), along with alem-
tuzumab (in most patients), using different donor sources (8
matched sibling donor, 13 matched family donor, 4, (A) pretransplant, (B) 100 days post-transplant, and (C) 1 year post-transplant.
Table 3
Percent Donor Chimerism at 30 Days and 1 Year after HSCT
Donor Peripheral Blood Day þ30 (%) Bone Marrow
Day þ100 (%)
Peripheral Blood 1 Year* (%) Bone Marrow
1 Year* (%)
Myeloid CD3þ CD19þ NK Myeloid CD3þ CD19þ NK
1 MRD 100 90 21 97 92 100 100 100 100 98
2 MRD 100 92 48 99 98 100 99 100 100 96
3 MRD 99 98 100 100 92 100 100 99 100 94
4 URD 100 94 100 100 97 100 100 100 100 94
5 URD 100 95 99 100 96 99 100 99 99 94
6 URD 100 100 ND 100 93 100 100 100 100 95
HSCT indicates hematopoietic stem cell transplant; MRD, matched related donor, URD, unrelated donor; ND, not done.
* Chimerism at 1 year.
J. Cuellar-Rodriguez et al. / Biol Blood Marrow Transplant 21 (2015) 1037e1045 1043haploidentical donor, and 45 unrelated donor), the overall
survival rate was 81% [19]. Only 2 patients rejected, more
than one-half had 100% donor chimerism by 1 year post-
transplant, and the remaining patients had stable mixed
chimerism.
In DOCK8 deﬁciency the aim of HSCT is to reverse the
clinical phenotype of DNA viral infections and sinopulmo-
nary infections and to correct the underlying immunologic
defects. In this regard, the severe viral infections in patients
with DOCK8 deﬁciency result from defects in T cell numbers
and function [17,20]. DOCK8 deﬁciency results in a selective
decrease in the number of circulating, naive CD8þ Tcells [16].
CD8 T cell proliferation is reduced in most DOCK8 patients0 
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Figure 4. Reconstitution of cellular compartments after HSCT. Leukocyt[2]. In humans with DOCK8 deﬁciency, most CD8þ T cells
display a CD45RAþ/CCR7 phenotype, a pattern associated
with cell exhaustion or replicative senescence [16]. This
phenotype may reﬂect chronic viral infections.
The recurrent sinopulmonary infections in DOCK8 deﬁ-
ciency are typical of humoral immunodeﬁciency or defects in
B cell activation. DOCK8 was shown to be involved in B cell
proliferation and Ig production in which Toll-like receptor 9
responses were decreased in DOCK8-deﬁciency B cells. Loss
of function mutations in DOCK8 in the mouse disrupts
memory B cell development in the germinal centers [16,17].
Several groups have described allogeneic HSCT in DOCK8
deﬁciency using a variety of conditioning regimens withre-transplant Post-transplant
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used a myeloablative dose of conditioning. Interestingly,
Bittner et al. [8] described a 2 year-old girl who received 8/8
HLA-matched bone marrow from her father after condi-
tioning with cyclophosphamide 60 mg/kg for 2 days,
ﬂudarabine 40 mg/m2/day for 4 days, and 400 cGy total body
irradiation. The patient had immunologic correction of the
DOCK8 deﬁciency phenotype. However, 6 years later she
remained with mixed donor chimerism, 98% donor T cells,
35% donor B cells, and only 6% donor neutrophils, suggesting
a higher intensity regimen is required to achieve donor
myeloid cell engraftment.
The most extensive review of HSCT in DOCK8 deﬁciency
retrospectively collected data from 18 institutions world-
wide: 32 patients were identiﬁed (some already published as
single case reports). The conditioning regimen among in-
stitutions included no conditioning, myeloablative and
nonmyeloablative conditioning, and different donor sources.
The overall survival ratewas 77%, and Tcell chimerismvaried
between 50% and 100%. Correction of the phenotype was
seen in 16 of 19 assessable patients (unpublished abstract
from the 15th biennial meeting of the European Society for
Immunodeﬁciencies (ESID), M. H. Albert, October 2012).
We used the combination of busulfan and ﬂudarabine
because this regimen has been shown to result in reliable
engraftment with a low regimen-related toxicity in hema-
tologic malignancies [21-24]. In our study, although only 1
patient received targeted busulfan, because of a decreasing
age of our patients we are now routinely using dose-targeted
busulfan with a .8-mg test dose administered 7 to 10 days
before the start of conditioning.
In our study all 6 patients had rapid engraftment with
high levels of donor chimerism with minimal regimen-
related toxicity. All clinical manifestations of DOCK8 deﬁ-
ciency resolved post-transplant. The clinical correction
correlated with laboratory evidence of decreased IgE levels
and eosinophils, along with a lymphocyte proﬁle consistent
with a new immunologic equipoise.
The incidence of acute GVHD in this study was compa-
rable with reported outcomes in HSCT series, with only 1
patient requiring systemic steroids. Only 1 patient (Patient 3)
had deﬁnitive evidence of chronic GVHD. However, the pa-
tient with extensive bronchiectasis and severe lung
dysfunction pretransplant (Patient 5) had initial improve-
ment and then worsening of her lung disease due to
suspected bronchiolitis obliterans syndrome. However, she is
now off all immunosuppression 2 years post-transplant.
A caveat of this study that makes it problematic to
compare with other transplant studies is that PIDs are a very
heterogeneous group, and there is every reason to suspect
that the T, Bþ, NK variants (ie, X-SCID) may respond to
allogeneic transplant very differently from the T, B, NKþ
variants (Rag deﬁciency, Artemis), the Tþ, Bþ, NKþ cohort
(chronic granulomatous disease and leukocyte adhesion
deﬁciency type 1), or even the Tþ, B, NK (GATA2
deﬁciency) patients. DOCK8 patients do not have the che-
mosensitivity seen in the T, B, NKþ variants or the
deep-seated fungal infections seen in the chronic granulo-
matous disease and leukocyte adhesion deﬁciency type 1
patients or the predisposition to acute myelogenous leuke-
mia seen in the GATA2 patients. Moreover, we used a
myeloablative conditioning regimen, only 10/10 matched
donors, and bone marrow in 4 of 6 patients. Thus, the
favorable outcomes we observed may be due to a unique
constellation of factors, including the disease itself.In summary, allogeneic HSCT in DOCK8 deﬁciency results
in reconstitution of the deﬁcient lymphocyte compartments
that are present pretransplant and complete reversal of the
clinical phenotype. The conditioning regimen had minimal
regimen-related toxicity, despite the degree of infections in
this cohort of patients, and resulted in reliable full donor
engraftment. With genetic testing for DOCK8 deﬁciency now
more widely available, we anticipate that earlier diagnosis
will enable patients to be transplanted earlier in their clinical
course, before signiﬁcant organ damage or the development
of viral-driven malignancies.
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